Market News / Story
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
Stocktwits ·
Stocktwits reports: Shares of Ultragenyx Pharmaceutical (RARE) were in focus after the biotech company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, giving it sizeable non-dilutive capital to support its pipeline. RARE shares were up 4% at the time of writing, bucking the broader market drawdown and on track for their biggest single-day gain so far this month. Genglycos Is Ultragenyx’s Third PRV Sale A Priority Review Voucher (PRV) lets its recipient…